274. Osteogenesis Imperfecta Clinical trials / Disease details
Clinical trials : 87 / Drugs : 103 - (DrugBank : 20) / Drug target genes : 14 - Drug target pathways : 76
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2004-005275-42-IT (EUCTR) | 21/03/2005 | 23/01/2008 | Study on the effect of r-hGH in combination with bisphosphonate treatment on bone metabolism in Osteogenesis Imperfecta | Study on the effect of r-hGH in combination with bisphosphonate treatment on bone metabolism in Osteogenesis Imperfecta | Osteogenesis Imperfecta MedDRA version: 6.1;Level: SOC;Classification code 10010331 | Trade Name: GENOTROPIN*1TBF 5,3MG (16UI) INN or Proposed INN: Somatropin Trade Name: NERIXIA*INFUS IV CONC 2F 100MG INN or Proposed INN: VARI | AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA | NULL | Not Recruiting | Female: yes Male: yes | Italy |